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Abstract 
Background: NLRP3 inflammasome has been implicated in the pathogenesis of systemic lupus erythematosus 
(SLE). The activation of NLRP3 inflammasome results in the production of IL-1β and the subsequent inflammation. 
Anti-dsDNA antibodies (anti-dsDNA Abs) play critical roles in the development and progression of SLE. However, 
the mechanism of NLRP3 inflammasome activation in SLE is still not known. This study investigated the activation of 
NLRP3 inflammasome stimulated by anti-dsDNA Abs in monocytes/macrophages from SLE patients.
Methods: Monocytes/macrophages from SLE patients or healthy controls were stimulated with anti-dsDNA Ab-posi-
tive serum or purified anti-dsDNA Abs. Activation of inflammasome was measured by flow cytometry or Western blot. 
Anti-dsDNA Abs isolated from active SLE patients were injected into female (NZB × NZW) F1 mice and the activation 
of NLRP3 inflammasome and the frequencies of Th17 and Treg were examined.
Results: The activity of caspase-1 was significantly increased in active SLE patients and was correlated with serum 
levels of anti-dsDNA Abs and disease activities. The concentrations of IL-1β and IL-17A were also significantly higher in 
SLE patients compared to healthy controls. Anti-dsDNA Ab-positive serum rather than healthy serum or RF (rheuma-
toid factor)-positive serum stimulated the activation of caspase-1 in monocytes. Anti-dsDNA Abs bound to TLR4 on 
macrophages and induced the production of ROS. Mitochondria-targeting antioxidant Mito-TEMPO, IκB kinase inhibi-
tor peptide or TLR4 siRNA inhibited the activation of NLRP3 inflammasome and the secretion of IL-1β induced by anti-
dsDNA Abs. Injection of anti-dsDNA Abs into (NZB × NZW) F1 mice resulted in increased caspase-1 activation and 
production of IL-1β and IL-17A. The Th17/Treg cell ratio also significantly increased following anti-dsDNA Ab injection.
Conclusions: Anti-dsDNA Abs activated NLRP3 inflammasome in monocytes/macrophages from SLE patients by 
binding to TLR4 and inducing the production of mitochondrial ROS.
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Background
Systemic lupus erythematosus (SLE) is a systemic auto-
immune disease with multiple organs involvement [1]. 
Despite the advances in the treatment of SLE, the mor-
bidity and mortality of the disease remain high [2]. Dys-
regulation of immune system plays a critical role in the 
initiation and progression of SLE. Overproduction of 
cytokines and the subsequent inflammation are involved 
in the pathogenesis of SLE [3]. IL-1β is a proinflamma-
tory cytokine that has been linked to SLE. It has been 
demonstrated that IL-1β is elevated in the serum of SLE 
patients [3, 4] and IL-1 receptor antagonist led to clinical 
and serological improvement [5]. In addition, IL-1β−/− 
and IL-1α/β−/− mice are resistant to the induction of 
experimental lupus [6].
Inflammasomes are a family of molecular platforms 




*Correspondence:  zsuyns@163.com 
†Hui Zhang and Rong Fu contributed equally to these works 
1 Department of Rheumatology, First Affiliated Hospital, Sun Yat-sen 
University, 58 Zhongshan Road II, Guangzhou 510080, China
Full list of author information is available at the end of the article
Page 2 of 12Zhang et al. J Transl Med  (2016) 14:156 
macrophages. Inflammasomes are activated by infection 
or danger signals and trigger the maturation of proin-
flammatory cytokines such as IL-1β to engage in innate 
immune response [7]. NLRP3 inflammasome is one of 
the most studied members. Activation of NLRP3 inflam-
masome involves the recruitment of adapter protein 
apoptosis-associated speck like protein (ASC) through 
homotypic PYD-PYD interaction. ASC subsequently 
recruits pro-caspase-1 via CARD-CARD contact in turn. 
The oligomerization of NLRP3 inflammasome leads to 
autocatalytic activation of caspase-1, which converts 
inactive pro-IL-1 into bioactive form [8]. NLRP3 inflam-
masome can be activated by either exogenous or endog-
enous stimuli [9–11].
Anti-double stranded DNA (anti-dsDNA) antibodies 
are the hallmark antibodies of SLE [12]. Anti-dsDNA 
antibodies are correlated with disease activity [13] and 
involved in the pathogenesis of SLE [14]. Anti-dsDNA 
antibodies presented in the blood before disease onset 
[15] and administration of anti-dsDNA antibodies from 
SLE patients into NZBWF1/J mice resulted in acceler-
ated lupus [16]. Data showed that anti-dsDNA antibod-
ies stimulated the expression and secretion of IL-1β 
from mononuclear cells and monocytes [17, 18]. It 
implies that anti-dsDNA antibodies might initiate and 
promote the disease by stimulating the production of 
IL-1β.
Recently, we have showed that NLRP3 inflammasome 
was activated in a mouse model of SLE, and inhibition 
of NLRP3 inflammsome activation resulted in decreased 
inflammation and improved disease severities [19, 20]. 
However, factors that trigger the activation of NLRP3 
inflammasome in SLE patients are not well defined. In 
the present study, by using purified anti-dsDNA antibod-
ies from active SLE patients, we showed that anti-dsDNA 
antibodies activated NLRP3 inflammasome in mono-
cytes/macrophages by binding to TLR4 and inducing 




In this study, 72 patients from the First Affiliated Hos-
pital, Sun Yat-sen University who fulfilled the American 
College of Rheumatology criteria for the classification 
of SLE [21] and 36 age and sex matched healthy donors 
were enrolled. Patients with comorbidities of cancers or 
infections were excluded. Disease activity was scored 
using SLE Disease Activity Index (SLEDAI) scoring sys-
tem [22]. Only patients with moderate to severe disease 
activity were included in the study (defined as SLE-
DAI  >  4) [23]. Demographic and clinical characteristics 
of the SLE patients are shown in Table 1.
Monocyte isolation and macrophage differentiation
Human peripheral blood mononuclear cells (PBMCs) were 
isolated from SLE patients or from healthy controls with 
Ficoll-Hypaque by density gradient centrifugation. Cells 
were cultured in antibiotic-free RPMI 1640 medium con-
taining 10  % FCS, 2  mM glutamate, 50  mM 2-ME, and 
10  mM HEPES buffer in 24-well plates. To obtain mono-
cytes, PBMCs were seeded to the culture dishes for 3 h to let 
the monocytes to adhere. Three hours later, non-adherent 
cells were washed away with PBS. To obtain macrophages, 
isolated monocytes were cultured with  culture  medium 
with 10 ng/ml of M-CSF for 7 days as previously described 
[24]. Culture medium was changed every 2 days.
Anti‑dsDNA antibody isolation
Anti-dsDNA antibody-positive sera were collected from 
active SLE patients. Healthy sera were used as con-
trols. Polyclonal anti-dsDNA antibodies were isolated 
from sera of SLE patients and control IgG from healthy 
subjects by affinity chromatography as we previously 
described [25]. Immune complexes were precipitated 
with polyethylene glycol (3.5 % [wt/vol]). Serum samples 
were then diluted with PBS and added to native DNA-
cellulose column (GE Biotech, USA). Non-DNA-bind-
ing fractions were flushed. DNA binding fractions were 
eluted with a linear NaCl gradient. IgG was isolated with 
protein G Sepharose affinity chromatography kits (GE 
Biotech, USA) and the purities of eluted IgG were con-
firmed by 10  % sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis (≥90 %).
Cell culture
PBMCs from SLE patients or healthy controls were iso-
lated and 1  ×  106 cells were seeded to 48-well culture 
Table 1 Demographical and  clinical characteristics of  the 
SLE patients (n = 72)
The healthy control group consisted 4 men and 32 women with a mean ± SD, 
age of 28 ± 10.7 years
SLE systemic lupus erythematosus, Anti-dsDNA anti-double stranded DNA 
antibodies, SLEDAI systemic lupus erythematosus disease activity index
a,b Concentration of 0–0.9 IU/ml was recognized as negative in this assay
Age (years) 30.2 ± 12.6
Sex (male/female) 7/65
Newly-onset (no.) 27
Kidney involvement (no.) 42
ESR (mm/h) 39.1 ± 24.8
CRP (mg/L) 7.7 ± 12.3
Anti-dsDNA Abs (IU/ml)a 2.7 ± 1.6
ANA (IU/ml)b 7.4 ± 3.2
C3 (g/L) 0.5 ± 0.3
C4 (g/L) 0.1 ± 0.06
SLEDAI 9.2 ± 5.9
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plate. Non-adherent cells were washed away and cells 
were maintained at 37 °C in 5 % CO2 in a humidified cell 
culture incubator. Monocytes isolated from PBMCs were 
stimulated with healthy serum, rheumatoid factor (RF)-
positive serum from rheumatoid arthritis (RA) patients, 
anti-dsDNA antibody-positive serum from SLE patients, 
or purified anti-dsDNA antibodies for 16 h. In addition, 
monocytes from SLE patients or healthy controls were 
stimulated with anti-dsDNA antibodies or control IgG 
for 16  h. Macrophages differentiated from SLE mono-
cytes were stimulated with anti-dsDNA antibodies or 
control IgG for 16 h. Unless otherwise stated, drug con-
centrations were used as the following: Mito-TEMPO 
((2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)-
2-oxoethyl) triphenylphosphonium chloride) (100  μM) 
(Sigma, Shanghai, China), glyburide (20  μM) (Sigma, 
Shanghai, China), Ac-YVAD-CMK (50  μM) (Calbio-
chem, Hong Kong, China) or IκB kinase inhibitor peptide 
(200  μM) (Calbiochem, Hong Kong, China). Cells were 
stimulated with 100  ng/ml of LPS for 6  h and 5  μM of 
ATP were included for the last 2  h, which was used as 
positive control. Supernatant was collected and frozen at 
−80 °C until tested.
Detection of anti‑dsDNA antibodies binding to TLR4
Monocytes/macrophages from SLE patients were 
acquired as described above. Cells were collected and 
incubated with anti-CD16/CD32/CD64 antibodies (Bio-
legend, San Diego, CA, USA) to block Fc receptor before 
incubated with control IgG or anti-dsDNA antibodies. 
Briefly, cells were incubated with control IgG (5  μg/ml) 
or different concentrations of anti-dsDNA antibodies at 
4  °C for 1  h. Cells were washed and stained with APC-
anti-Toll-like receptor-4 (TLR4) antibody (Biolegend, San 
Diego, CA, USA) at 4 °C for 30 min. Data were acquired 
by flow cytometer FACS Aria (BD Bioscience, San Jose, 
CA, USA).
Transfection
One million THP-1 cells (a human monocytic cell line, 
ATCC, USA) were seeded to 6-well culture plates. Cells 
were stimulated with 100  nM of PMA for 18  h. Briefly, 
cells were washed and transfected with 50  nM TLR4 
siRNA (Ruibo-bio, Guangzhou, China) together with 
Lipofectamine 2000 (Invitrogen, New York, USA) in 
500  μl Opti-MEM I Reduced-Serum Medium (Invitro-
gen, New York, USA) at 37 °C in a CO2 incubator. Cells 
were also transfected with 50  nM of scramble siRNA 
complexed with Lipofectamine 2000. The RNAi-Lipo-
fectamine complex was removed after incubated for 6 h, 
and the cells were cultured overnight in RPMI plus 10 % 
FBS. Twenty-four hours after transfection, cells were 
maintained with serum-free medium for 24  h prior to 
use. Then THP-1 cells were incubated with 10 μg/ml of 
anti-dsDNA antibodies or IgG control for 16 h.
Mice experiments
Female (NZB  ×  NZW) F1 mice (The Jackson Labora-
tory, USA) of 24-week of age were used in this study. 
Mice were kept in specific pathogen free condition in Sun 
Yat-sen University Animal Facility. Chow and water were 
supplied ad libitum. Mice were divided into three groups, 
control group, control IgG group and anti-dsDNA anti-
body group (n = 8). Mice received intraperitoneal injec-
tion of control vehicle, 100 μg of control IgG or 100 μg of 
anti-dsDNA antibodies in 100 μl PBS. The injection was 
repeated once 3  days later. Mice were sacrificed by car-
diac puncture under anesthesia on day 7. Anticoagulated 
blood was collected and plasma was isolated by centrifu-
gation, which were frozen at −80 °C until being analyzed 
for the concentrations of IL-1β and IL-17A. White blood 
cells were collected by lysing red blood cells. Spleens 
were collected and single cell suspension was prepared 
for the measurement of Th17 cells and regulatory T cells 
(Treg) by flow cytometry.
Flow cytometry
To determine the activation of caspase-1 intracel-
lularly, a fluorescence-labeled inhibitor specific for 
caspase-1 (FLICA) probe (ImmunoChemistry Technolo-
gies, Bloomington, MN, USA) was used as previously 
described [26]. Cells were collected and incubated with 
FLICA in 37 °C for 30 min. Cells were washed and ana-
lyzed by flow cytometry. For measuring mitochondria 
membrane potential (ΔΨm), Rhodamine 123 (Sigma, 
Shanghai, China) was used as previously described [27]. 
2,7-dihydrochlorofluorescein (DHCF) (Sigma, Shang-
hai, Chiba) was used to measure the production of ROS 
in the cells [28]. To detect the frequency of Th17 cells 
in the spleen, single cell suspension was prepared from 
the spleen and 1 × 106 cells was stimulated with 50 ng/
ml phorbolmyristate acetate (PMA) plus 500 ng/ml iono-
mycin (Sigma, Shanghai, China) for 5 h, with inclusion of 
10  μg/ml of brebeldin A (eBiosciences, San Diego, CA, 
USA) in the last 2 h. Cells were fixed, permeabilized, and 
stained with PE-anti-IL-17A (BD Pharmingen, San Jose, 
CA, USA) after stained with FITC-anti-CD4 antibodies 
(BD Pharmingen, San Jose, CA, USA). To analyze the fre-
quency of Foxp3+ Treg in the spleen, 1 × 106 cells were 
stained with anti-CD4 antibody (eBioscience, San Diego, 
CA, USA). Cells were fixed, permeabilized, and stained 
with PE-Cy5-anti-Foxp3 antibody (eBioscience, San 
Diego, CA, USA). Data was analyzed by Flowjo software 
(Tree Star Inc, Ashland, OR, USA).
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Western blot
Cells were collected and protein was extracted. Briefly, 
extracted cellular proteins were loaded to SDS–poly-
acrylamide gels. Protein was electrotransferred onto pol-
yvinylidinedifluoride membranes. The membranes were 
blocked with 5  % bovine serum albumin in TBST and 
incubated with anti-ASC (Novus, Littleton, CO, USA), 
anti-caspase-1 p10, anti-P2X7 receptor (P2X7R), anti-
Cathepsin-B (Abcam, Hong Kong, China), anti-pro-IL-1 
(Santa, Cruz Biotechnology, Dallas, TX, USA), or anti-
GAPDH (Kangcheng, Shanghai, China) primary antibod-
ies at 4 °C overnight. The membranes were then washed 
and incubated with horseradish peroxidase conjugated 
anti-rabbit IgG (Cell Signaling Technology, Beverly, MA, 
USA) at room temperature for 60  min, and the signals 
were detected by enhanced chemiluminescence.
Luminex assay
Human serum collected from SLE patients or healthy 
controls were frozen at −80 °C until analyzed by Luminex 
assay (Invitrogen, New York, USA), as measured on a 
Bio-Plex system (Bio-Rad, Hercules, USA). IL-1β and IL-
17A were included in the multiplex analysis kit. For the 
measurement of IL-1β and IL-17A in mouse serum, com-
mercial ELISA kits (eBioscience, San Diego, USA) were 
used according to the manufacturer’s instructions.
Statistical analyses
The data was expressed as the mean  ±  SD. Statistical 
analysis was performed using SPSS 13.0 (SPSS Inc, Chi-
cago, USA). The differences were assessed by t test, or 
one way ANOVA with or without repeated measure-
ments followed by Bonferroni’s multiple comparison post 
test as appropriate. Correlation analyses were done by 
Spearman’s rank correlation test. Two-tailed p <0.05 was 
considered statistically significant.
Results
Inflammasome was activated in SLE and correlated 
with serum anti‑dsDNA antibody level
Our previous study has shown that caspase-1 was acti-
vated in a mouse model of SLE [8]. To measure the 
activity of caspase-1 in active SLE patients, we used a flu-
orescence-labeled inhibitor probe (FLICA), which binds 
to intracellular active caspase-1 specifically. The medium 
fluorescence intensity (MFI) of active capase-1 in mono-
cytes of active SLE patients was significantly higher than 
that of the healthy controls (Fig. 1a, b). Since the produc-
tion of IL-1β and IL-17A is increased following NLRP3 
activation, we then measured serum concentration of 
IL-1β and IL-17A in these patients. Serum levels of IL-1β 
and IL-17A in SLE patients were significantly higher 
than those of healthy controls (Fig.  1c, d). Serum level 
of IL-1β was correlated with capase-1 activities in active 
SLE patients (Fig.  1e). Interestingly, the MFI of active 
capase-1 was also correlated with serum anti-dsDNA 
antibody level (Fig. 1f ), suggesting the possibility of anti-
dsDNA antibodies in triggering NLRP3 inflamasome 
activation. The MFI of caspase-1 was also correlated with 
disease activity index, the SLEDAI (Fig. 1g).
Anti‑dsDNA antibodies activate NLRP3 inflammasome 
in monocytes/mocrophages from SLE patients
Monocytes isolated from SLE patients were stimulated 
with different stimuli (serum from healthy controls, RF-
positive serum from RA patients, anti-dsDNA antibody-
positive serum from SLE patients and LPS  +  ATP). 
Anti-dsDNA antibody-positive serum stimulation 
resulted in the activation of inflammasome in mono-
cytes. However, healthy control serum or RF-positive 
serum did not activate inflammasome as measured by 
flow cytometry by using FLICA (Fig. 2a). Previous study 
showed that anti-dsDNA antibodies from SLE patients 
stimulated the overproduction of IL-1 from mononuclear 
cells [17]. To study the mechanism of anti-dsDNA anti-
bodies in the production of IL-1, anti-dsDNA antibodies 
isolated from active SLE patients were used to stimulate 
monocytes. There was marked activation of inflamma-
some in monocytes stimulated with anti-dsDNA anti-
bodies as measured by FLICA (Fig.  2b). On the other 
hand, anti-dsDNA antibodies also activated inflam-
masome in monocytes from healthy controls (Fig.  2c). 
Monocytes from active SLE patients had higher acti-
vation level of NLRP3 inflammasome following anti-
dsDNA antibody stimulation than that from healthy 
controls (Fig.  2c). Furthermore, anti-dsDNA antibodies 
stimulated the activation of NLRP3 inflammasome in 
monocyte-derived macrophages (Fig. 2d), resulting in the 
production of IL-1β (Fig.  2e). Glyburide, which specifi-
cally inhibits NLPR3 inflammasome activation [10], was 
used to inhibit NLRP3, and capase-1 inhibitor YVAD was 
used to inhibit caspase-1. Glyburide and YVAD signifi-
cantly inhibited the activation of NLRP3 inflammasome 
and the production of IL-1β stimulated by anti-dsDNA 
antibodies (Fig.  2d, e). It implied that anti-dsDNA anti-
bodies activated NLRP3 inflammasome in monocytes/
macrophages from SLE patients.
Anti‑dsDNA antibodies activate NLPR3 inflammasome 
in macrophages via production of mitochondria‑derived 
ROS
Monocyte-derived macrophages from SLE patients 
were stimulated with anti-dsDNA antibodies for differ-
ent duration. Macrophages were incubated with DCHF-
DA and analyzed by flow cytometry. The production of 
ROS started to increase 1  h after anti-dsDNA antibody 
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stimulation and continued to increase up to 4 h (Fig. 3a). 
In addition, anti-dsDNA antibodies from active SLE 
patients affected the function of mitochondria as evi-
dent by decreased mitochondria membrane potential 
(ΔΨm) (Fig. 3b). However, there was no increase in the 
expression of P2X7R and cathepsin-B, the upstream mol-
ecules of NLRP3 inflammasome (Fig. 3c). The activation 
of NLRP3 inflammasome stimulated by anti-dsDNA 
antibodies was inhibited by mitochondria-targeting 
antioxidant Mito-TEMPO. The expression of ASC and 
caspase-1 p10 and the production of IL-1β were signifi-
cantly reduced by pre-treatment with Mito-TEMPO in 
the culture system (Fig. 3d, e).
Anti‑dsDNA antibodies regulated the activation of NLRP3 
inflammasome by binding to TLR4
Monocytes/macrophages are rich in Fc receptor (FcR). 
IgG can bind to cell surface by interacting with FcR 
through Fc region. To rule out the binding of IgG to 
FcR, FcR was blocked by using anti-CD16/CD32/CD64 
antibodies before incubation with anti-TLR4 antibody. 
Cells were then pre-treated with anti-dsDNA antibodies 
before incubation with anti-TLR4 antibody. The bind-
ing of anti-TLR4 antibody to monocyte-derived mac-
rophages was completely blocked by pre-treatment 
with anti-dsDNA antibodies but not with control IgG 
(Fig. 4a). The activation of NLRP3 inflammasome stimu-
lated by anti-dsDNA antibodies was further confirmed 
in THP-1 cell line. TLR4-specific siRNA was used to 
deplete TLR4 in THP-1 cells and gene silencing was 
confirmed by flow cytometry (Fig.  4b). Anti-dsDNA 
antibodies stimulated the activation of NLRP3 inflam-
masome as evident by increased expression of Caspase-1 
p10 in THP-1 cell line (Fig.  4c). The expression of cas-
pase-1 p10 was significantly inhibited by TLR4-specific 
siRNA (Fig. 4c). The production of IL-1β was also signifi-
cantly decreased (Fig.  4d). Interestingly, the expression 
of pro-IL-1 and ASC was also significantly inhibited by 
TLR4-specific siRNA. Furthermore, IκB kinase inhibi-
tor peptide significantly decreased the expression of 
pro-IL-1 and the activation of NLRP3 inflammasome 
(Fig.  4c, d). These data implied that anti-dsDNA anti-
bodies activated NLRP3 inflammasome by binding to 
TLR4 in macrophages.
Fig. 1 Activation of inflammasome in monocytes from active SLE patients. a, b PBMCs were isolated from active SLE patients (n = 72) or healthy 
controls (HC) (n = 36). The activation of caspase-1 in monocytes was measured by flow cytometry and cells were gated on monocyte popula-
tion. The activation of caspase-1 in SLE patients was significantly higher than that of healthy controls. c, d Serum levels of IL-1β and IL-17A were 
significantly higher in active SLE patients than that of healthy controls. e Serum level of IL-1β was correlated with MFI of active caspase-1. f MFI of 
active caspase-1 was correlated with serum level of anti-dsDNA antibody. g MFI of active caspase-1 was correlated with SLEDAI. **p < 0.001, vs HC. 
α-dsDNA anti-dsDNA antibodies
Page 6 of 12Zhang et al. J Transl Med  (2016) 14:156 
Fig. 2 Anti-dsDNA antibodies from SLE patients activated inflammasome in monocytes/macrophages. a Monocytes from SLE patients were 
stimulated with different stimuli (health control serum, RF positive serum, anti-dsDNA antibody-positive serum, LPS + ATP or vehicle control). The 
activation of caspase-1 was measured by flow cytometry. Anti-dsDNA antibody-positive serum from SLE patients increased the activity of cas-
pase-1 in monocytes. Healthy control serum or RF-positive serum from RA patients did not affect the activity of caspase-1. b SLE monocytes were 
stimulated with IgG from healthy controls or anti-dsDNA antibodies from SLE patients. Anti-dsDNA antibodies increased the activity of caspase-1. 
Healthy control IgG had no effect on the activity of caspase-1 in monocyte. c Monocytes from healthy controls or SLE patients were stimulated with 
anti-dsDNA antibodies. Activation of caspase-1 in SLE monocytes was significantly increased as compared to monocytes from healthy controls. d, e 
SLE Monocyte derived macrophages were stimulated with anti-dsDNA antibodies. Anti-dsDNA antibodies stimulated the activation of inflammome, 
which can be inhibited by NLRP3 inhibitor glyburide or caspase-1 inhibitor Ac-YVAD-CMK. Each experiment was repeated for three times. *p < 0.01, 
**p < 0.001. α-dsDNA anti-dsDNA antibodies; RF rheumatoid factor
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Fig. 3 Anti-dsDNA antibodies activated inflammasome by increasing the production of ROS. a Monocyte-derived macrophages from SLE patients 
were stimulated with anti-dsDNA antibodies for different duration and incubated with DHCF-DA. Anti-dsDNA antibodies increased the production 
of ROS in macrophages. b Monocyte-derived macrophages from SLE patients were stimulated with anti-dsDNA antibodies and incubated with 
Rhodamine 123. Anti-dsDNA antibodies decreased mitochondria membrane potential (ΔΨm) in macrophages. c Monocyte-derived macrophages 
from SLE patients were stimulated with anti-dsDNA antibodies and the expression of P2X7R and cathepsin-K was measured by western blot. There 
was no significant change in the expression of P2X7R and cathepsin-K when stimulated with anti-dsDNA antibodies. d, e The activation of inflam-
masome in macrophages was inhibited by mitochondrial-targeting Mito-TEMPO when stimulated with anti-dsDNA antibodies. Each experiment 
was repeated for three times. **p < 0.001. α-dsDNA anti-dsDNA antibodies
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Anti‑dsDNA antibodies activated NLRP3 inflammasome 
in vivo and impaired the balance of Th17/Treg cells
Anti-dsDNA antibodies were injected into female 
(NZB × NZW) F1 mice. Healthy control IgG or vehicle 
was used as controls. Anti-dsDNA antibodies stimulated 
the activation of inflammasome in monocytes of mice 
receiving anti-dsDNA antibody injection (Fig. 5a). In the 
anti-dsDNA antibody-injected mice, serum concentra-
tion of IL-1β and IL-17A was significantly higher as com-
pared to control IgG or vehicle injected mice (Fig.  5b, 
c). The frequency of Th17 cells significantly increased in 
anti-dsDNA antibody-injected mice (Fig. 5d, e). However, 
Fig. 4 TLR4-NF-κB signal pathway regulated the activation of inflammasome stimulated by anti-dsDNA antibodies. a SLE monocyte-derived 
macrophages were incubated with anti-CD16/CD32/CD64 antibodies to block FcR before incubated with different concentrations of anti-dsDNA 
antibodies. Cells were then stained with TLR4 antibody. Data was acquired by flow cytometry. Anti-dsDNA antibodies bound to TLR4 as shown by 
the flow charts. b THP-1 cells were treated with TLR4-specific siRNA or scramble siRNA. The depletion of TLR4 was confirmed by flow cytometry. c, d 
THP-1 cells were stimulated with anti-dsDNA antibodies and the activation of inflammasome was measured by western blot. Anti-dsDNA antibod-
ies stimulated the activation of inflammasome in THP-1 cells, which was inhibited by depleting TLR4 or by inhibition of NF-κB. Each experiment was 
repeated for three times. **p < 0.001. α-dsDNA anti-dsDNA antibodies
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the frequency of CD4+Foxp3+ Treg cells significantly 
decreased in anti-dsDNA antibody-injected mice com-
pared to control IgG or vehicle-injected mice (Fig. 5f, g).
Discussion
The activation of NLRP3 inflammasome is associated 
with the pathogenesis of autoimmune diseases [29]. It 
has been shown that NLRP3 inflammasome activation is 
involved in the pathogenesis of lupus mouse models [19] 
and in human [30]. NLRP3 inflammasome can be acti-
vated by diverse exogenous stimuli, such as silica [31]; 
or endogenous stimuli, such as islet amyloid polypeptide 
[10]. In the present study, we found that NLRP3 inflam-
masome was activated in monocytes from SLE patients. 
In addition, anti-dsDNA antibodies isolated from 
active SLE patients stimulated caspase-1 activation and 
increased IL-1β production in monocytes/macrophages, 
suggesting that anti-dsDNA antibodies activate NLRP3 
inflammasome. Our finding are in consistency with the 
report by Shin et  al. [18] showing that dsDNA alone 
could not induce IL-1β production and could induce 
IL-1β production only in the presence of serum contain-
ing anti-dsDNA antibodies. Interestingly, we found that 
the activation level of NLRP3 inflammasome in mono-
cytes was correlated with serum anti-dsDNA antibody 
level and disease activity in SLE patients.
Anti-dsDNA antibodies were present in the blood 
before disease onset and the level of anti-dsDNA anti-
bodies is correlated with disease activity [15]. Injection of 
anti-dsDNA antibodies from SLE patients promoted dis-
ease progression in NZBW F1/J mice [16]. To further con-
firm the pathogenic relevance of our in vitro findings and 
those from Shin MS et al. [18], we injected anti-dsDNA 
antibodies from SLE patients into female (NZB × NZW) 
F1 mice. This resulted in the in vivo activation of NLRP3 
inflammasome in monocytes and increased produc-
tion of IL-1β. Injection of allogenic IgG into mice might 
result in non-specific activation of NLRP3 inflamma-
some. However, this is unlikely since injection of human 
IgG from healthy controls did not stimulate the activa-
tion of NLRP3 inflammasome or increase the production 
of IL-1β. Therefore, these data suggest that anti-dsDNA 
antibodies may be involved in the pathogenesis of lupus 
by activating NLRP3 inflammasome.
The activation of NLRP3 inflammasome has been asso-
ciated with different mechanisms: production of ROS 
[32], potassium efflux [33] and the release of cathepsin B 
into cytoplasm [34]. The production of ROS had a critical 
role for the development of renal injuries in SLE patients 
[35, 36]. However, what cause the production of ROS and 
how ROS promotes the disease is still not clear. In this 
study, anti-dsDNA antibodies were showed to stimu-
late the production of ROS in monocytes/macrophages. 
In addition, the activation of NLRP3 inflammasome in 
monocytes/macrophages was inhibited by mitochon-
dria-targeting antioxidant Mito-TEMPO, suggesting 
that the mitochondrial ROS production stimulated 
by anti-dsDNA antibodies mediates the activation of 
NLRP3 inflammasome. However, we did not observe 
increased expression of K+ channel P2X7R or cathepsin 
B in monocytes/macrophages stimulated by anti-dsDNA 
antibodies.
Mitochondria is the major organelle that generates 
ROS and decreased mitochondria membrane potential 
is related to ROS production [37]. It has been demon-
strated that mitochondria function was in associate with 
the activation of NLRP3 inflammasome [38] and mito-
chondria-derived ROS is responsible for the activation of 
NLRP3 inflammasome [39]. In this study, we found the 
anti-dsDNA antibody stimulation resulted in decreased 
mitochondria membrane potential, suggesting that acti-
vation of NLRP3 inflammasome by anti-dsDNA antibod-
ies was mediated through stimulating ROS production in 
mitochondria.
Recent data showed that NF-κB signal priming is essen-
tial for the activation of NLRP3 inflammasome [40]. The 
stimulation of TLR4 leads to the activation of NF-κB and 
expression of IL-1 [41]. Previous study showed that TLR9 
and NF-κB were essential in producing IL-β by human 
monocytes in response to self dsDNA and anti-dsDNA 
antibodies [18]. In this study, anti-dsDNA antibodies were 
shown to bind to TLR4, leading to increased expression 
of pro-IL-1 and the activation of NLRP3 inflammasome, 
and finally the secretion of IL-1β from monocytes/mac-
rophages. Gene silencing of TLR4 or inhibition of NF-κB 
signal significantly reduced the expression of pro-IL-1 and 
ASC, and suppressed the formation of active caspase-1 in 
THP-1 cell-derived macrophages. These results indicate 
that anti-dsDNA antibodies bind to TLR4, activate TLR4-
NF-κB and NLRP3 inflammasome signal pathway.
Th17 is a newly identified subpopulation of CD4 
T cells that is expanded in SLE patients and plays an 
important role in the pathogenesis of SLE [42]. Previ-
ous study showed that the activation of NLRP3 inflam-
masome promoted the differentiation of Th17 cells [26]. 
In this study, the serum level of IL-17A was significantly 
higher in active SLE patients. The activation of NLRP3 
inflammasome might be involved in the differentiation 
of Th17 cells. This speculation is supported by the in vivo 
data. Injection of anti-dsDNA antibodies into female 
(NZB  ×  NZW) F1 mice resulted in NLRP3 activation, 
increased production of IL-1β and IL-17A and increased 
Th17/Treg ratio. The activation of NLRP3 inflammasome 
stimulated by anti-dsDNA antibodies might promote dis-
ease severity by expanding Th17 cells and screwed the 
balance of Th17/Treg.
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Fig. 5 Anti-dsDNA antibodies stimulated the activation of inflammasome in vivo and impaired the balance of Th17/Treg. Anti-dsDNA antibod-
ies isolated from active SLE patients, vehicle or control IgG from healthy patients were injected into female (NZB × NZW) F1 mice (n = 8) twice. 
Spleens and blood were collected 7 days later. a The activation of inflammasome in monocytes was measured by flow cytometry. Cells were gated 
on CD11b+ cells. Anti-dsDNA antibodies activated the inflammasome in vivo as compared to control IgG or vehicle. b The concentration of IL-1β 
in the serum was significantly higher in the serum of anti-dsDNA antibody-injected mice compared to control IgG or vehicle-injected mice. c 
Serum concentration of IL-17A was also significantly higher in anti-dsDNA antibody-injected mice. d, e The frequency of Th17 cells was significantly 
higher in anti-dsDNA antibody-injected mice as compared to control IgG or vehicle-injected mice. f, g The frequency of CD4+Foxp3+ Treg cells was 
significantly lower in anti-dsDNA antibody-injected mice as compared to control IgG or vehicle-injected mice. **p < 0.001. α-dsDNA anti-dsDNA 
antibodies
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Conclusion
Anti-dsDNA antibodies from SLE patients can activate 
NLRP3 inflammasome in monocytes/macrophages by 
binding to TLR4 and activating TLR4-NF-κB signal path-
way. The activation of NLRP3 inflammasome stimulated 
by anti-dsDNA antibodies is dependent on the produc-
tion of mitochondrial ROS. This study provides new evi-
dence in the pathogenesis of SLE that might be used as a 
potential treatment target for the disease.
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